THDB(SH:600867) Zheng Quan Shi Bao Wang·2026-01-26 11:09Core Viewpoint - Tonghua Dongbao (600867) is expected to achieve a net profit of approximately 1.242 billion yuan in 2025, marking a turnaround from a loss in 2024, driven by strong domestic sales and international expansion [1][2] Group 1: Financial Performance - The company reported a total profit of -144 million yuan and a net profit attributable to shareholders of -42.72 million yuan in 2024 [1] - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 402 million yuan in 2025 [1] Group 2: Business Growth Drivers - The main drivers for the anticipated profit increase include the rapid growth of insulin products in the domestic market, leveraging advantages from insulin procurement, and significant sales increases in products like liraglutide injection and empagliflozin tablets [1][2] - The company is focusing on innovation and transformation, with plans to enhance its product pipeline and expand into new therapeutic areas beyond diabetes, including obesity and non-alcoholic fatty liver disease (NASH) [2] Group 3: International Expansion - The company has made significant progress in its international strategy, with insulin products approved in several emerging markets, including Uzbekistan, Nicaragua, Myanmar, Indonesia, and the Dominican Republic [3] - Collaborations, such as with Sinovac Biotech for liraglutide injection, have facilitated entry into overseas markets, with successful GMP audits in Egypt and Colombia [3][4] Group 4: Future Outlook - The company plans to continue expanding its portfolio of insulin and GLP-1 products into international markets, aiming to deepen and broaden its global business reach [4]